Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95972
UPID:
BMP15_HUMAN
Alternative names:
Growth/differentiation factor 9B
Alternative UPACC:
O95972; Q17RM6; Q5JST1; Q9UMS1
Background:
Bone morphogenetic protein 15, also known as Growth/differentiation factor 9B, plays a pivotal role in ovarian follicular development. It acts as an oocyte-specific growth/differentiation factor, crucial for folliculogenesis and granulosa cell growth.
Therapeutic significance:
Linked to Ovarian dysgenesis 2 and Premature ovarian failure 4, both resulting from gene variants, understanding Bone morphogenetic protein 15's function could pave the way for novel treatments for these ovarian disorders.